Under the agreement, Roche will co-develop and co-commercialize bexobrutideg in the United States while holding exclusive commercialization rights outside the U.S., with Nurix receiving royalties in the low- to high-teens range. The transaction remains subject to Hart-Scott-Rodino antitrust clearance, with both parties expecting closing in the third quarter of 2026.
Bexobrutideg is a late-stage asset positioned to compete directly with Eli Lilly's Jaypirca in the BTK inhibitor space. The deal reflects Roche's strategic commitment to hematology and oncology, where BTK-targeting drugs represent a significant commercial category. Attorneys tracking oncology partnerships should monitor the HSR approval timeline and watch how Roche's co-development structure affects the competitive dynamics of the BTK degrader market as the asset moves toward pivotal trials.